# Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection

> **NCT01900015** · PHASE4 · COMPLETED · sponsor: **Juan Macías** · enrollment: 45 (actual)

## Conditions studied

- HCV Coinfection
- HIV Infection

## Interventions

- **DRUG:** Raltegravir
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT01900015
- **Lead sponsor:** Juan Macías
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-03
- **Primary completion:** 2017-01-17
- **Final completion:** 2017-01-17
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2017-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01900015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01900015, "Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01900015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*